NUFORMIX PLC Logo

NUFORMIX PLC

Pharmaceutical developer using cocrystal technology to repurpose drugs for fibrosis.

NFX | IL

Overview

Corporate Details

ISIN(s):
GB00BYW79Y38
LEI:
2138003XG3H3I2J3BJ24
Country:
United Kingdom
Address:
6TH FLOOR, EC3V 0HR LONDON

Description

Nuformix PLC is a pharmaceutical development company focused on drug repurposing to address unmet medical needs, particularly in fibrosis and oncology. The company utilizes its expertise in cocrystal technology to unlock the therapeutic potential of approved drugs. This strategy involves creating new solid forms of existing medicines to improve their physical properties and performance, aiming to develop novel treatments with potentially accelerated development timelines.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2021-09-13 08:00
Licensing agreement with Oxilio for NXP001
English 13.3 KB
2021-08-24 12:57
Result of AGM
English 28.6 KB
2021-07-23 14:35
Posting of Annual Report and Notice of AGM
English 9.8 KB
2021-07-22 08:00
Letter to shareholders re: Dr Anne Brindley
English 10.1 KB
2021-07-21 17:41
Second Price Monitoring Extn
English 2.8 KB
2021-07-21 17:36
Price Monitoring Extension
English 2.8 KB
2021-07-21 08:00
Directorate Change
English 11.1 KB
2021-07-15 08:00
Final results for the year ended 31 March 2021
English 512.2 KB
2021-06-10 10:25
Holding(s) in Company
English 47.1 KB
2021-06-07 08:00
Notice of Allowance of Patent in US
English 10.4 KB
2021-06-01 08:00
Project update - Progress on NXP002 and NXP004
English 12.2 KB
2021-05-24 08:00
Directorate Changes
English 12.9 KB
2021-05-12 12:35
Holding(s) in Company
English 49.2 KB
2021-05-11 14:51
Holding(s) in Company
English 48.9 KB
2021-04-22 15:06
Second Price Monitoring Extn
English 2.8 KB

Automate Your Workflow. Get a real-time feed of all NUFORMIX PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for NUFORMIX PLC

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for NUFORMIX PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

1NKEMIA Logo
Biotechnology company providing R&D and services for the life sciences sector.
Spain
IKM
2cureX AB Logo
Develops an IVD test using 3D tumoroids to predict patient response to cancer drugs.
Sweden
2CUREX
Abera Bioscience AB Logo
Develops mucosal vaccines using a proprietary Outer Membrane Vesicle (OMV) platform.
Sweden
ABERA
Clinical-stage biopharma developing therapeutics for oncology and viral diseases.
South Korea
203400
ABL Bio Inc. Logo
Develops bispecific antibody therapeutics for oncology and neurodegenerative diseases.
South Korea
298380
Abpro Holdings, Inc. Logo
Clinical-stage biotech developing antibody therapeutics for oncology and ophthalmology.
United States of America
ABP
Absci Corp Logo
A generative AI drug creation company developing biologic medicines.
United States of America
ABSI
Achiko AG Logo
A digital services platform for cross-border business compliance and engagement.
Switzerland
ACHI
Active Biotech Logo
Biotechnology company developing drugs for oncology and inflammatory eye disorders.
Sweden
ACTI
Adagene Inc. Logo
Clinical-stage biotech developing antibody-based immunotherapies for oncology.
United States of America
ADAG

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.